Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

Completed · Phase 4 · Has a placebo group

Conditions studied: Menstruation Disturbances

In brief

The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.

Key facts

Study ID

NCT02070692

Run by

Oregon Health and Science University

People needed

56

Starts

2014-02-01

Expected to finish

2015-12-01

Last updated by the study team

2017-07-02

Who can join

Age: 15 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Current user of the etonogestrel implant (Nexplanon, Implanon) for at least one month
• Experiencing bleeding episodes more frequently than every 24 days, or a single episode of bleeding lasting longer than 14 days
• English or Spanish speaking
• Planning to continue implant use for six months
• Access to a cell phone that can accept and send text messages

You may not qualify if…

• Postpartum within six months
• Post-abortion within six weeks
• Pregnant
• Breast-feeding
• Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant
• Bleeding dyscrasia
• Anticoagulation use
• Active cervicitis
• Allergy to tamoxifen
• History of venous thromboembolism
• Current or past breast or uterine malignancy
• Use of medication contraindicated with tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital)

Where it is running

• Oregon Health & Science University (OHSU) — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.